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a)	 needle syringe Programs:	sterile	needles	and	syringes	are	provided	through	needle	syringe	programs	(NSP)	at	no	or	low	cost	as	
well	as	advice	on	injection	behaviour,	safe	sex	and	referral	to	other	services.	Injection	drug	users	were	the	target	population.	
b)	 Adult male circumcision: would	be	a	program	to	circumcise	men	having	sex	with	men	(MSM)	to	prevent	HIV	acquisition.	Four	
target	groups	were	compared:	young	MSM;	MSM	aged	35-44	years	(highest	incidence	of	HIV	acquisition);	insertive	MSM;	and	all	
MSM.	




e)	 Early use of antiretrovirals for treatment and/or prevention:	initiation	of	ARVs	in	all	patients	with	HIV	regardless	of	
CD4	T-cell	count.	






























Table 1: Health impact, costs and incremental cost-effectiveness ratios for six HIV interventions  
Interventions  
Health impact  
(95% CI or interquartile 
range-IQR) 
Annual 
budget  ICER 
ICER  
(95% CI)   
Needle Syringe 
Programs 
75,000 HIV infections (IQR 
41,000-84,000)  
190,000 HCV infections 




Cost-saving  $2.3bn  
(IQR $1.7-$4.0bn)  
Circumcision 
240 to 650 HIV infections 
prevented 
1.4%-3.7% of expected 
incidence 
1,800 to 4,900 DALYs 







cost-saving  cost-saving 
Circumcision 
 All MSM 
$8,900/DALY cost-saving to 
$45,000 
Circumcision 
 35-44 year olds 








HIV prevalence could fall to 
6.8% over 20 years vs rise 
to 14% with no program.  
95,000 DALYs (55,000 to 
160,000) 














3 HIV infections prevented  
per year 
540 DALYs (430 to 660) 
$3m-$5m $190,000/DALY  
$170,000  to 
$210,000 
Early Rx alone 11,000 DALYs (3,600 to 
20,000)  
$40m  $140,000/DALY $65,000 to 
$350,000 
Early Rx with 
prevention effect 
12,000 DALYs (5400-
14,000) including Rx and 
prevention  
$40m  $59,000/DALY 
cost-saving to 
$143,000 
Anal cytology 2000 (0 to 14,000 )  
DRE 





$33,000/DALY vs nil 
cost-saving to 
$330,000 










Table 2: The stakeholders ranked the interventions after the economic analyses.  
Decision  Intervention  Main reason  
Should fund 
Needle Syringe Programs 
Pre-exposure prophylaxis 
Cost-saving 
Impact on epidemic 
Could fund 
Circumcision  
Early use of treatment as 
prevention 
Potentially cost-saving 
May be cost-effective if prevention 
effect within plausible limits  
Don’t fund 




Not likely to be cost-effective 
Not good value for money 



























Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
General population results 
1.    Adult depression 
2.    Alcohol 
3.    Blood pressure and cholesterol lowering 
4.    Cannabis 
5.    Cervical cancer screening, Sunsmart and PSA screening 
6.    Childhood mental disorders 
7.    Fruit and vegetables 
8.    HIV 
9.    Obesity 
10.  Osteoporosis 
11.   Physical activity 
12.   Pre diabetes screening 
13.   Psychosis 
14.    Renal replacement therapy, screening and  
early treatment of chronic kidney disease
15.   Salt 
16.   Suicide prevention 
17.   Tobacco   
paMpHlets in tHis series 
 
Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 










Table 3: Stakeholder ranking following second stage filter discussion 
 
Stakeholder decision  Intervention  Summary of second stage filters 
Should fund 
Needle Syringe Programs Generally acceptable now 
Pre-exposure prophylaxis  
Moral imperative to use available 
technology 




Indemnity risks if person denied 
service acquired HIV.  
Could fund 
Early use of treatment and/or as 
prevention Easy to implement  
Doubtful 
Circumcision  Feasibility and acceptability 
Anal cytology Feasibility and acceptability 
 
 
 
 
 
 
 
